Nirsevimab for respiratory syncytial virus infections

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 4 registered trials.

Why this status

  1. 7 Jun 2019: Trial registered, NCT03979313
  2. 23 Jul 2019: Trial started, NCT03979313
  3. 27 Jul 2023: Trial started, NCT06042049
  4. 18 Sep 2023: Trial registered, NCT06042049

The trials

NCT02878330: A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.

State
Completed
Phase
Phase 2
People
1,453 taking part
Started
3 Nov 2016
Primary completion
17 Jul 2018
Arms
MEDI8897 50 mg
Results
Posted on the registry
  1. 25 Aug 2016: Trial registered
  2. 3 Nov 2016: Trial started
  3. 6 Dec 2018: Trial completed
  4. 14 Oct 2019: Trial results posted

NCT03959488: A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

State
Completed
Phase
Phase 2 and Phase 3
People
925 taking part
Started
30 Jul 2019
Primary completion
3 May 2021
Arms
MEDI8897
Results
Posted on the registry
  1. 22 May 2019: Trial registered
  2. 30 Jul 2019: Trial started
  3. 20 Jan 2023: Trial completed
  4. 21 Sep 2023: Trial results posted

NCT03979313: A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

State
Completed
Phase
Phase 3
People
3,012 taking part
Started
23 Jul 2019
Primary completion
11 Mar 2021
Arms
MEDI8897
Results
Posted on the registry
  1. 7 Jun 2019: Trial registered
  2. 23 Jul 2019: Trial started
  3. 21 Mar 2023: Trial completed
  4. 28 Feb 2024: Trial results posted

NCT06042049: A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab

State
Completed
Phase
Phase 3
People
33 taking part
Started
27 Jul 2023
Primary completion
24 Jul 2025
Arms
MEDI8897
Results
Posted on the registry
  1. 27 Jul 2023: Trial started
  2. 18 Sep 2023: Trial registered
  3. 24 Jul 2025: Trial completed
  4. 16 Apr 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Nirsevimab (RSV-specific monoclonal antibody).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.